[go: up one dir, main page]

MA34645B1 - Nouvelles formes cristallines - Google Patents

Nouvelles formes cristallines

Info

Publication number
MA34645B1
MA34645B1 MA35870A MA35870A MA34645B1 MA 34645 B1 MA34645 B1 MA 34645B1 MA 35870 A MA35870 A MA 35870A MA 35870 A MA35870 A MA 35870A MA 34645 B1 MA34645 B1 MA 34645B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
new crystalline
pyridin
relates
ylamino
Prior art date
Application number
MA35870A
Other languages
English (en)
Inventor
Paul Allen Sutton
Michael J Girgis
Jessica Liang
Mahavir Prashad
Edwin Bernard Villhauer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34645(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34645B1 publication Critical patent/MA34645B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles formes cristallines du sel de sodium de l'acide (4-{4-[5-(6-trifluorométhyl-pyridin-3-ylamino)-pyridin-2-yl]-phényl}-cyclohexyl)-acétique, et leur utilisation dans le traitement ou la prévention d'un état pathologique ou d'un trouble associé à une activité de la DGAT1 chez l'animal, en particulier chez l'homme. L'invention concerne également des procédés de fabrication de telles nouvelles formes cristallines.
MA35870A 2010-10-07 2013-05-03 Nouvelles formes cristallines MA34645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39088810P 2010-10-07 2010-10-07
PCT/US2011/054841 WO2012047948A1 (fr) 2010-10-07 2011-10-05 Nouvelles formes cristallines

Publications (1)

Publication Number Publication Date
MA34645B1 true MA34645B1 (fr) 2013-11-02

Family

ID=44802409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35870A MA34645B1 (fr) 2010-10-07 2013-05-03 Nouvelles formes cristallines

Country Status (26)

Country Link
US (2) US8829194B2 (fr)
EP (2) EP2781516B1 (fr)
JP (1) JP6093703B2 (fr)
KR (2) KR101900652B1 (fr)
CN (1) CN103153981B (fr)
AR (1) AR083317A1 (fr)
AU (1) AU2011312185B2 (fr)
BR (1) BR112013008355A2 (fr)
CA (1) CA2813736C (fr)
CL (1) CL2013000929A1 (fr)
CO (1) CO6710909A2 (fr)
EC (1) ECSP13012608A (fr)
ES (2) ES2618411T3 (fr)
GT (1) GT201300089A (fr)
IL (1) IL225532A0 (fr)
MA (1) MA34645B1 (fr)
MX (1) MX2013003835A (fr)
NZ (1) NZ608557A (fr)
PE (1) PE20140337A1 (fr)
PH (1) PH12013500659A1 (fr)
PL (2) PL2781516T3 (fr)
PT (2) PT2781516T (fr)
RU (1) RU2612556C2 (fr)
SG (1) SG188586A1 (fr)
TW (1) TW201217360A (fr)
WO (1) WO2012047948A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2781516T (pt) * 2010-10-07 2017-03-15 Novartis Ag Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético
JP5815875B2 (ja) * 2011-09-12 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎ−（５−シクロアルキル−又は５−ヘテロシクリル）−ピリジン−３−イルカルボキサミド
AU2013254307B2 (en) * 2012-04-27 2016-05-26 Novartis Ag Cyclic bridgehead ether DGAT1 inhibitors
EP2841432A1 (fr) * 2012-04-27 2015-03-04 Novartis AG Inhibiteurs de dgat1 consistant en tétrahydropyranes
WO2013169648A1 (fr) * 2012-05-07 2013-11-14 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de dgat1 et un médicament abaissant la teneur en triglycérides
KR101646716B1 (ko) 2016-02-15 2016-08-08 서성환 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단
KR20210105931A (ko) * 2018-12-20 2021-08-27 머크 샤프 앤드 돔 코포레이션 Nrtti 화합물의 신규 결정질 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
AR044399A1 (es) 2003-05-20 2005-09-14 Novartis Ag Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
WO2005097085A1 (fr) 2004-04-08 2005-10-20 Micro Nutrient, Llc Systeme nutritif pour schemas posologiques individuels adaptes
EP2301923B1 (fr) * 2006-03-31 2016-06-08 Novartis AG Dérivés de pyridine comme inhibiteurs de dgat
BRPI0720023A2 (pt) * 2006-12-11 2018-09-04 Novartis Ag método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1
PT2781516T (pt) * 2010-10-07 2017-03-15 Novartis Ag Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético

Also Published As

Publication number Publication date
EP2625172B1 (fr) 2016-12-07
AU2011312185B2 (en) 2015-07-02
SG188586A1 (en) 2013-04-30
PL2781516T3 (pl) 2017-05-31
EP2781516B1 (fr) 2016-12-07
CL2013000929A1 (es) 2013-09-27
US20130184311A1 (en) 2013-07-18
PL2625172T3 (pl) 2017-07-31
PH12013500659A1 (en) 2021-03-03
CO6710909A2 (es) 2013-07-15
CN103153981B (zh) 2017-10-10
IL225532A0 (en) 2013-06-27
BR112013008355A2 (pt) 2016-06-14
KR101900652B1 (ko) 2018-09-19
EP2625172A1 (fr) 2013-08-14
CN103153981A (zh) 2013-06-12
CA2813736A1 (fr) 2012-04-12
RU2013120549A (ru) 2014-11-20
PT2781516T (pt) 2017-03-15
NZ608557A (en) 2015-02-27
JP2013539755A (ja) 2013-10-28
CA2813736C (fr) 2020-03-24
AU2011312185A1 (en) 2013-04-04
ECSP13012608A (es) 2013-07-31
US20140343102A1 (en) 2014-11-20
AR083317A1 (es) 2013-02-13
EP2781516A3 (fr) 2014-10-15
TW201217360A (en) 2012-05-01
KR20130115277A (ko) 2013-10-21
WO2012047948A1 (fr) 2012-04-12
RU2612556C2 (ru) 2017-03-09
JP6093703B2 (ja) 2017-03-08
GT201300089A (es) 2014-12-30
MX2013003835A (es) 2013-06-28
US8829194B2 (en) 2014-09-09
PT2625172T (pt) 2017-03-10
EP2781516A2 (fr) 2014-09-24
ES2618411T3 (es) 2017-06-21
KR20180011337A (ko) 2018-01-31
ES2618426T3 (es) 2017-06-21
PE20140337A1 (es) 2014-03-13

Similar Documents

Publication Publication Date Title
MA34645B1 (fr) Nouvelles formes cristallines
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
RU2013138733A (ru) Конденсированные производные аминодигидротиазина
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
NO20091198L (no) Azabenzotiofenylforbindelser og anvendelser derav
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
WO2009012482A3 (fr) Amides heterocycliques a 5 chainons et composes associes
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
DE602006021535D1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
Cantacessi et al. TIMPs of parasitic helminths–a large-scale analysis of high-throughput sequence datasets
MA33417B1 (fr) Compositions pharmaceutiques et formes solides
MA34377B1 (fr) Composé de pipéridinyle en tant que modulateur de l'activité des récepteurs des chimiokines
WO2013136069A3 (fr) Complément alimentaire et procédé de dosage
BR112014009165A2 (pt) sal e uso médico
CO6270359A2 (es) Moduladores de piperidinil y piperazinil de y-secretasa
DK1639106T3 (da) Proteaser
PT2523960E (pt) Derivados heterocíclicos de ácidos carboxílicos com um anel oxazolopirimidina substituído em 2,5
EA201100187A1 (ru) Селективные ингибиторы ммр-12 и ммр-13 на основе гидроксамовой кислоты